

Powered by **CARB-X** Projects formerly in the Pipeline

Sponsor	Product	Novelty			Description	Priority		Development Stage				Final Investment Date
		New Abx Class	New Non-traditional Product	New Target		CDC	WHO	Hit to Lead	Lead Optimization	Pre-Clinical	Phase I	
Achaogen	AkAO-LpxC	✓		✓	LpxC inhibitor	✓	✓			<i>P. aeruginosa</i>		2017-10-05
Achaogen	Next-Generation AG				Next-gen AG w/extended Gram-neg coverage (<i>Pseudomonas</i>)	✓	✓			Gram-neg activity including <i>Pseudomonas</i>		2019-03-31
Cidara Therapeutics	CD201		✓	✓	Bifunctional immunotherapy	✓	✓			<i>Acinetobacter + P. aeruginosa + Enterobacteriaceae</i>		2018-04-30
Curza	CZ-02	✓		✓	Novel class Gram-negative	✓	✓			Broad Spectrum		2019-04-15
Eligochem	Helical AMP	✓			Helical antimicrobial peptide	✓	✓			Gram-neg activity		2018-12-31
Melinta	Pyrrolocytosine	✓		✓	Novel class, MDR ESKAPE	✓	✓			Broad spectrum		2019-02-28
Recida Therapeutics	RC-01	✓		✓	LpxC inhibitor	✓	✓				Enterobacteriaceae + <i>P. aeruginosa</i>	2019-04-23
Redx Pharma	NBTI	✓			Dual-acting topoisomerase inhibitor	✓	✓			<i>Acinetobacter + P. aeruginosa + Enterobacteriaceae</i>		2017-10-25
Shionogi	AGN-BL				Novel Gram-negative lactam	✓	✓				Enterobacteriaceae	2018-09-05
Visterra	VIS705		✓	✓	Antibody-drug conjugate	✓	✓			<i>P. aeruginosa</i>		2018-09-30
Sponsor	Type	Technology	Description				Final Investment Date					
			Feasibility Demonstration	Optimization and Preparation for Development	Product Development	System Integration and						
MicrobeDx	Near care Dx	CD based microfluidics	Urinary Tract Infection				2018-08-31					